| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5894707 | Placenta | 2015 | 6 Pages |
Abstract
These data indicate that whilst inhibition of activin A signalling by the low molecular weight ALK kinase inhibitor, MKP-1-140A, reduced some of the physiological manifestations of pre-eclampsia, the potential for serious maternal and fetal side effects may preclude it from clinical applications.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
R. Lim, S. Adhikari, S. Gurusinghe, B. Leaw, R. Acharya, R. Rahman, R. Ciayadi, M. Potdar, G.F. Kelso, M.T.W. Hearn, E.M. Wallace,